Coding, drug billing, prior authorization and denial work for community oncology, hematology-oncology and infusion practices, inside the EHR you already use.
Oncology claims fail on small details with large dollar amounts attached: units built from the wrong HCPCS descriptor, a missing JZ modifier, or an approval written for last month's regimen. Any one of them holds the full drug line. Luxen's certified coders check drug units, waste modifiers, administration times and authorizations before the claim leaves, then work denials highest dollars first through full-service medical billing built for oncology practices.
On this page
Oncology billing services handle coding, drug billing, prior authorization, claims and denials for cancer practices, from chemotherapy administration codes such as 96413 to buy-and-bill drugs Medicare pays at ASP plus 6%. In Luxen's claim audit, JW or JZ drug waste modifiers were missing on 11% of single-dose vial claims.
Oncology billing changes with where treatment happens and who buys the drug.
We also bill the supportive lines these practices run: bone-modifying agents, IV iron, growth factors, port care and hydration. New oncologists and APPs also need payer enrollment in place before their first treatment day.
Oncology revenue leaks at the drug line, the administration code and the approval. Our denial and AR recovery team works these claims highest dollars first. Amounts are 2026 Medicare national non-facility rates.
| Scenario | Codes | What goes wrong | $ at stake per claim | Luxen audit finding |
|---|---|---|---|---|
| Chemotherapy IV push coded as a standard push | 96374 instead of 96409 | Antineoplastic push billed from the non-chemotherapy code family | $66.80 | Push codes checked against the drug given |
| Single-dose vial with no waste modifier | J9271 with JW or JZ | Drug line returned as unprocessable | Full drug line | JW or JZ drug waste modifiers were missing on 11% of single-dose vial claims |
| Dose billed in milligrams, not descriptor units | J9035, 10 mg per unit | 400 mg billed as 400 units instead of 40 | Full drug line, denied or recouped | Drug units did not match the documented dose on 7% of oncology drug lines |
| Visit on a treatment day with the complexity add-on | 99214-25, G2211, 96413 | G2211 denied when modifier 25 is for chemotherapy | $17.37 per visit | G2211 removed before submission |
| Regimen changed mid-course | J9299 with 96413 | Approval still lists the prior drug | Full drug and administration | Approvals matched to the current regimen |
| Clinical trial patient on routine care | Q1, Z00.6, NCT number | NCT number or trial diagnosis missing | $133.27 plus the visit | NCT number matched to the study record |
CMS applies chemotherapy administration codes to cytotoxic drugs and to monoclonal antibodies and other biologic response modifiers. Our certified medical coding team codes from the administration record, not the order.
| Code | What it covers | 2026 national non-facility |
|---|---|---|
| 96401 | Chemotherapy injection, subcutaneous or intramuscular, non-hormonal | $71.81 |
| 96402 | Chemotherapy injection, hormonal anti-neoplastic | $38.75 |
| 96409 | Chemotherapy IV push, single or initial drug | $104.54 |
| 96411 | Chemotherapy IV push, each additional drug | $57.12 |
| 96413 | Chemotherapy IV infusion, first hour | $133.27 |
| 96415 | Chemotherapy IV infusion, each additional hour | $28.39 |
| 96416 | Prolonged chemotherapy infusion started with a pump | $133.27 |
| 96417 | Sequential infusion of a different drug, first hour | $66.47 |
| 96523 | Irrigation of an implanted venous access device | $26.05 |
| 99214 / 99215 | Established patient visit | $135.61 / $192.39 |
| G2211 | Visit complexity add-on | $17.37 |
Rates are total non-facility RVUs times the $33.4009 conversion factor, before locality adjustment.
Medicare Part B pays most separately payable drugs at 106% of average sales price (ASP). Qualifying biosimilars are paid at their own ASP plus 8% of the reference product ASP for five years. The 2% sequestration cut applies to Medicare's 80% share, so a practice that collects the full 20% coinsurance nets about ASP plus 4.3%.
| HCPCS | Drug | Unit | Example dose | Units billed |
|---|---|---|---|---|
| J9271 | Pembrolizumab | 1 mg | 200 mg | 200 |
| J9299 | Nivolumab | 1 mg | 480 mg | 480 |
| J9035 | Bevacizumab | 10 mg | 400 mg | 40 |
| J9045 | Carboplatin | 50 mg | 600 mg | 12 |
| J9267 | Paclitaxel | 1 mg | 300 mg | 300 |
Doses are examples. Units always come from the HCPCS descriptor, never the vial size.
Since July 1, 2023, Medicare requires JZ on separately payable drugs from single-dose containers when nothing is discarded, and JW on a separate line for any discarded amount. Since October 1, 2023, claims without the right modifier can be returned as unprocessable, in offices and hospital outpatient departments alike. Manufacturers owe CMS refunds when discarded amounts pass 10% for most refundable drugs, so waste data gets audited.
Since January 1, 2025, every 340B covered entity, hospital-based or not, reports the TB modifier on 340B-acquired Part B drugs; JG ended December 31, 2024. CMS uses TB to remove 340B units from Part B inflation rebates. Medicaid requires the NDC on physician-administered drug claims so the state can collect manufacturer rebates.
Medicare covers routine costs in qualifying trials under NCD 310.1. Each claim needs:
Items and services the sponsor customarily provides free are not covered, so the sponsor budget and the payer bill have to be split before the first dose.
The Enhancing Oncology Model began July 1, 2023 and runs to June 30, 2030. Participants bill Monthly Enhanced Oncology Services with HCPCS M0010: $110 per beneficiary per month, or $140 for dual eligible patients. It covers seven cancers: breast, chronic leukemia, small intestine and colorectal, lung, lymphoma, multiple myeloma and prostate. The Oncology Care Model ended June 30, 2022, so any workflow still built around it needs rework.
The rule: CMS applies chemotherapy administration codes to monoclonal antibodies and other biologic response modifiers (Medicare Claims Processing Manual, Chapter 12, section 30.5). The cost: 96365 pays $67.14 against $133.27 for 96413, so $66.13 is lost on every first hour. In our claim audit, coding and modifier errors caused 21% of denials.
The rule: 99211 is not reportable with chemotherapy administration codes (NCCI Policy Manual, Chapter XI). The cost: the visit is denied, or paid and recouped on audit. In our billing reviews, 19% of denied claims were never reworked or appealed.
The rule: JW goes on any discarded amount from a single-dose container, and JZ goes on lines with none (CMS JW and JZ modifier FAQs). The 10% figure is the manufacturer refund threshold, not a billing threshold. The cost: the whole drug line can be returned. Duplicate claim denials made up 9% of denials, mostly from resubmitting instead of correcting.
The rule: Minnesota bars prior authorization for NCCN-consistent antineoplastic treatment from January 1, 2026, except treatment that is a medication (Minn. Stat. 62M.07). The cost: the full drug line when nobody requests approval. Missing or invalid prior authorization caused 17% of denials in our claim audit.
The rule: Medicare also requires Z00.6 and the 8-digit NCT number, plus condition code 30 on institutional claims (Medicare Claims Processing Manual, Chapter 32, section 69). The cost: routine care denied while claims sit in rework against the 12-month filing limit. Timely filing caused 6% of denials, and only 4% of those were recovered.
We run the revenue cycle from eligibility to zero balance inside the practice management system you already use. How full-service billing works.
Certified coders review charges against your documentation and payer rules before the claim goes out, so the denial is prevented rather than appealed. Medical coding.
Aged and denied claims are worked to resolution, then the upstream cause is fixed so the same claims stop coming back. Denials and AR recovery.
Benefits are verified and authorizations secured before the appointment, which is the cheapest place in the cycle to stop a denial. Eligibility and prior authorization.
Statements, balance questions and payment plans are handled by the same team that worked the claim. Patient billing.
Payer enrollment and re-credentialing are tracked through to approval, so a lapsed credential never quietly stops payment. Credentialing.
A HIPAA-trained front-office assistant working inside your EHR on calls, scheduling, intake and referrals, alongside the billing team. Medical virtual assistant.
We work inside the oncology systems your practice already runs, with no migration.
We sign the BAA before access and bill from the treatment plans, administration records, drug logs and approvals your team already keeps.
2 weeks
from a signed BAA to our team working your claims
About 3 weeks
to the first recovered payments on aged AR
20+ years
combined billing and coding experience
Luxen claim audit (61,400 claims audited, Jan 2025 to Jun 2026) and Luxen client data (38 client practices, Jan 2024 to Jun 2026):
Small discrepancies in drug units, NDC data, and discarded quantities were delaying our highest-value oncology claims. Luxen created a drug-to-administration audit and recovered $204,700 in four months.
Revenue Cycle Director, community oncology practice
Treatment regimens changed faster than our authorization spreadsheet could keep up. Luxen connected approvals to the active plan of care, reducing oncology charges held for authorization review from $318,000 to $54,000.
Practice Administrator, medical oncology and infusion center
Full engagements are written up in our dental practice case study and our ambulance billing case study.
Prior authorization is where oncology cash stalls. Our eligibility and prior authorization team ties each approval to the current regimen, drug, dates and site of care.
| Metric | Luxen figure |
|---|---|
| Days in AR, oncology | Oncology practices carried a median 44 days in AR (Luxen billing reviews) |
| Days in AR after onboarding | Median days in AR dropped from 54 to 33 within 120 days (Luxen client data) |
| Clean claim rate | Clean claim rate rose from 89.6% to 97.3% in the first 90 days (Luxen client data) |
| Monthly AR review | Practices that reviewed AR ageing monthly carried 12 fewer days in AR (Luxen billing reviews) |
Cancer patients carry large balances, and the rules differ by benefit. Our patient billing team sets expectations before treatment starts.
Unworked balances cost money: practices lost 3.1% of collections to patient balances written off before a second statement, while plain-language statements plus text reminders raised patient collections 22% across 14 practices (Luxen client data).
3% to 6% of collections
Luxen's pricing generally falls between 3% and 6% of collections, depending on claim volume, specialty, payer mix, and how much of the revenue cycle your practice hands over.
Higher-volume practices usually land toward the lower end. Smaller or more complex practices land higher because there is more work per account. There is no setup fee and no exit fee, and the agreement runs month to month with 30 days notice.
A lower fee attached to weak billing is still expensive. The number that matters is what your collections do after you hire someone.
Luxen charges 3% to 6% of collections, set by drug volume, payer mix and authorization workload. No setup or exit fee.
| Service line | Monthly collections | Luxen at 3% | Luxen at 6% |
|---|---|---|---|
| Buy-and-bill drugs | $104,000 | $3,120 | $6,240 |
| Administration and visits | $48,000 | $1,440 | $2,880 |
| Labs and other services | $8,000 | $240 | $480 |
| Total | $160,000 | $4,800 | $9,600 |
| Cost | In-house | Luxen |
|---|---|---|
| Monthly | $12,640 (7.9% of collections) | $4,800 to $9,600 |
| Annual | $151,680 | $57,600 to $115,200 |
| When a biller leaves | Open biller roles took a median 67 days to fill | No gap in coverage |
| Terms | Salaries, benefits and software | Month to month, 30 days notice |
Fully loaded in-house billing cost 7.9% of collections for practices under $2M, across 96 practices that shared payroll data (Luxen billing reviews). This example practice collects $1.92M a year.
| Partner type | Drug line checks | Authorization tracking | Reporting | Terms |
|---|---|---|---|---|
| In-house biller | Depends on one person | Shared with nurses and front desk | Built by your staff | Payroll and turnover |
| Generalist billing company | Usually after a denial | Often not included | Standard aging | Often annual |
| Specialty oncology billing company | Drug-focused | Sometimes a separate fee | Varies | Varies |
| EHR vendor RCM | Vendor templates | Limited | Inside the platform | Bundled with software |
| Luxen | Pre-bill check on every drug line | Included, tied to the regimen | Monthly denials and AR by drug and payer | Month to month, 30 days notice |
Compare medical billing companies before you sign.
A 30-minute look at your AR ageing, denial reasons and payer mix. You leave knowing what is recoverable, what we would work first and what it would cost.
We sign a business associate agreement before anyone touches your system. Your named team then works inside the practice management system and clearinghouse you already use. Nothing is migrated, and claims are being worked within two weeks of the signed BAA.
Aged and denied claims come first because that is revenue you have already earned. Most practices see the first recovered payments inside three weeks.
Once the backlog is moving, we take over the agreed part of the daily cycle: eligibility, coding review, submission, posting, denials and patient balances.
You know who owns your claims. The team works inside the practice management system and EHR you already run, with no migration.
Claims are coded by certified coders against your documentation and payer rules. Automation handles the repetitive checks so people spend their time on the claims that need judgment.
We sign a business associate agreement before accessing protected health information, and access is limited to the named people on your account.
We look at your AR ageing, volume, payer mix and denial profile first, then tell you what we believe is recoverable and what it would cost.
A billing company is a poor fit if you are not willing to share visibility into your billing, if the vendor uses a rotating pool of people who never learn your practice, or if it cannot explain why your claims are being denied. Be wary of anyone promising large collection increases before they have seen your AR ageing. The right partner makes your revenue cycle more visible, not less.
Chemotherapy administration uses CPT 96401 to 96549, with 96413 for the first hour of an IV infusion, 96415 for each additional hour and 96417 for a sequential drug. Drugs are billed with HCPCS J codes in the units set by each descriptor, such as J9271 pembrolizumab at 1 mg per unit. Visits on treatment days need modifier 25 when separately identifiable.
Outsourced oncology billing is usually priced as a percentage of collections. Luxen charges 3% to 6%, so a practice collecting $160,000 a month pays $4,800 to $9,600. There is no setup or exit fee, and terms are month to month with 30 days notice.
About 2 weeks from a signed BAA to working claims, with first recovered payments in about 3 weeks. We start with the oldest and highest-dollar drug claims, because Medicare only accepts claims filed within 1 calendar year of the date of service.
Yes. We work inside your existing oncology EHR and practice management system, so there is no migration. We sign the BAA before access and bill from the treatment plan, administration record and drug log already in the system.
Routine costs are billed under NCD 310.1 with the Q1 modifier, investigational services with Q0, diagnosis Z00.6 and the 8-digit NCT number. Institutional claims also need condition code 30. Items the sponsor customarily provides free are not billed to Medicare.
Thirty minutes, no deck and no fee. We look at what is sitting past 90 days and where your denials cluster, and you leave knowing what is recoverable, what we would work first, and what it would cost.
Book a Billing Review%20(1).avif)
